Analysts Set Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Price Target at $22.70

Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) has been given an average recommendation of “Moderate Buy” by the seven analysts that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $22.70.

A number of equities analysts have recently issued reports on SENS shares. TD Cowen reiterated a “buy” rating on shares of Senseonics Holdings, Inc. Common Stock in a report on Thursday, January 8th. Stifel Nicolaus set a $9.00 target price on Senseonics Holdings, Inc. Common Stock in a research report on Tuesday, March 3rd. Finally, Weiss Ratings initiated coverage on Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, February 17th. They issued a “sell (d-)” rating for the company.

Insider Buying and Selling

In other Senseonics Holdings, Inc. Common Stock news, CEO Timothy T. Goodnow bought 17,225 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were bought at an average price of $5.79 per share, for a total transaction of $99,732.75. Following the transaction, the chief executive officer directly owned 651,243 shares in the company, valued at $3,770,696.97. This trade represents a 2.72% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Douglas A. Roeder purchased 17,500 shares of the stock in a transaction on Friday, March 13th. The stock was acquired at an average cost of $5.73 per share, with a total value of $100,275.00. Following the completion of the purchase, the director directly owned 119,731 shares of the company’s stock, valued at $686,058.63. The trade was a 17.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of SENS. Aristides Capital LLC bought a new stake in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at about $139,000. Virtu Financial LLC purchased a new stake in Senseonics Holdings, Inc. Common Stock during the 4th quarter valued at about $188,000. Quadrature Capital Ltd bought a new position in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $321,000. Balyasny Asset Management L.P. bought a new position in Senseonics Holdings, Inc. Common Stock during the 4th quarter worth approximately $91,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Senseonics Holdings, Inc. Common Stock in the 4th quarter worth approximately $972,000. 12.36% of the stock is owned by institutional investors.

Senseonics Holdings, Inc. Common Stock Price Performance

SENS opened at $6.48 on Friday. Senseonics Holdings, Inc. Common Stock has a 52 week low of $5.25 and a 52 week high of $15.74. The company has a current ratio of 4.83, a quick ratio of 4.55 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $270.67 million, a P/E ratio of -3.83 and a beta of 0.90.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.